

# Will you succeed in CJR-X?

## *How to Build a CMS-Aligned View of Your Bundled Payments*

**Pamela Pelizzari, Principal**

**Alyssa Pennini, Senior Healthcare Product Director**

SEPTEMBER 24, 2026



Milliman MedInsight

# Meet the Milliman Team



**Pamela Pelizzari**

Milliman  
Principal



**Alyssa Pennini**

Milliman  
Senior Healthcare Product Director

# Agenda

## Welcome

- Introductions
- 

## The Basics

- What to expect in TEAM and CJR-X
- 

## Why Now?

- What you can do to set yourself up for success early
- 

## Key Questions

- What does your organization need to know
- 

## Planning

- What are the key dates and what to prepare for next
-

# Poll 1

## Which teams do you primarily represent or support?

- Clinicians and care teams
- Quality and patient safety
- Finance, actuarial, and contracting
- Population health, payers, and value-based care
- Other (let us know in the chat)

## Poll 2


### **How prepared do you feel to support CJR-X at your hospital in 2028?**

- Very prepared - I already hit the ground running
- Somewhat prepared - strong in some areas; need improvement in others
- Not prepared - significant work needed
- Not applicable - I'm not a CJR-X participant

# Today's goal

Create a focused strategy for success in CJR-X, and identify gaps for immediate intervention

The countdown to CJR-X is on – so the time is now to focus on closing the gaps.




# The Basics

What to expect in a CMS  
bundled payment program

# Why Bundled Payments?

Bundled payments are a value-based financial model, aiming to lower costs and increase quality by holding providers accountable for episodes of care.



# History of CMS Bundled Payment Models




# CJR-X

An overview and how it will  
impact your organization

# What is the Comprehensive Care for Joint Replacement Expanded (CJR-X)?

## Overview

CJR-X is a nationwide mandatory episode-based model



### Who is impacted?

Acute care hospitals paid under both the IPPS and OPPS, not selected for participation in TEAM (and not in Maryland)

### How do payments flow?

Payments in real-time are unchanged, with a retrospective reconciliation after each performance year

### How are targets set?

Based on risk-adjusted and trended regional historical spending, adjusted for quality performance

### What is the level of risk?

Upside and downside risk (20%) with limited downside risk (5%) for certain hospital types

# How does CJR-X differ from TEAM?

## Episodes



### Hospitals Included

- CJR-X covers all eligible hospitals nationally, except those already included in TEAM or those located in Maryland



### Episode Definition

- CJR-X has only one episode, Lower extremity joint replacement (LEJR)
- CJR-X episodes include services within 90 days following the anchor discharge or procedure, significantly longer than TEAM's 30 days



### Quality Metrics and Impact

- CJR-X has a set of more established and focused quality measures, including patient-reported outcomes for both inpatient and outpatient cases, compared to TEAM
- CJR-X uses quality as a threshold for payment (lowest-scoring hospitals **cannot** achieve savings)

# What patterns have we seen as CMS launched TEAM (1/1/2026)?



## Use of many legacy systems

- CMS has learned how to run models using various tools and contractors – and we're seeing the same structures, and issues, with this model.



## Lack of key details

- Communication from CMS related to participant questions has not always been consistent – we have seen some questions answered quickly, and some go unanswered.



## Data delays and errors

- The data needed to support the model was slow to arrive and has already undergone multiple rounds of revision.

# **Performance Management – Why now?**

# What is needed to succeed in TEAM and CJR-X?



**On-The-  
Ground  
Operations**



**Clinical  
Leadership**



**Analytic  
Infrastructure**

# Long Term Impacts of CJR-X Management

- We are seeing **substantial challenges** among TEAM participants who didn't start early:
  - Lack of clear care management goals
  - Lack of buy-in from key clinical and operational stakeholders
  - Shortfalls in post-acute KPIs
- **Now is the time to start planning, so you can avoid these issues in CJR-X.**



# Key Questions for CJR-X Participants

And how you can answer  
them, **with time to  
intervene.**

## Key questions for CJR-X participants:

- 1 What is my projected CJR-X episode volume?
- 2 How significant is that volume, and cost, in my total book of business?
- 3 How will I perform against projected CJR-X targets?
- 4 How do my post-acute care patterns compare to national or regional benchmarks?
- 5 Do I have the internal support to succeed in care transformation?

# Use the data that is available now to understand financial impacts


What is my total episode volume, and thus my total financial exposure?

How many episodes will I be held accountable for?

What is the total expected gain or loss?


How is my post-acute performance? Is there opportunity to improve?

How does that gain or loss break down across patients?



# Zoom in on the metrics that really matter

How can post-acute care drive savings?



| Post-Anchor Site           | Estimated Episode Count | Post-Anchor Utilization | Regional Average Benchmark | Est Reduction if Util Shifted 100% Towards Reg Avg | Est Savings if Util Shifted 100% Towards Reg Avg | Top 10th Percentile Benchmark | Est Reduction if Util Shifted 100% Towards Top 10th Percentile | Est Savings if Util Shifted 100% Towards Top 10th Percentile |
|----------------------------|-------------------------|-------------------------|----------------------------|----------------------------------------------------|--------------------------------------------------|-------------------------------|----------------------------------------------------------------|--------------------------------------------------------------|
| ER Stand Alone Utilization | 1,266                   | 12.7%                   | 13.4%                      | 0.0%                                               | \$9,500                                          | 13.0%                         | 0.0%                                                           | \$12,800                                                     |
| HH Utilization             | 1,266                   | 46.9%                   | 63.6%                      | 0.0%                                               | \$19,300                                         | 17.1%                         | 29.8%                                                          | \$950,400                                                    |
| IRF Utilization            | 1,266                   | 5.1%                    | 6.1%                       | 0.0%                                               | \$252,100                                        | 2.2%                          | 3.0%                                                           | \$1,053,300                                                  |
| Readmit Rate               | 1,266                   | 5.2%                    | 6.6%                       | 0.0%                                               | \$66,700                                         | 5.4%                          | 0.0%                                                           | \$92,200                                                     |
| SNF Utilization            | 1,266                   | 7.4%                    | 9.3%                       | 0.0%                                               | \$532,900                                        | 8.2%                          | 0.0%                                                           | \$588,200                                                    |
| SNF ALOS                   | 1,266                   | 36.8                    | 30.1                       | 6.7                                                | \$413,000                                        | 27.7                          | 9.1                                                            | \$576,100                                                    |
| Total                      | 1,266                   |                         |                            |                                                    | \$1,293,400                                      |                               |                                                                | \$3,273,100                                                  |

What post-acute care opportunity do I have?


How does my utilization compare to benchmarks, and how could that translate into savings?

# Surface physician-level variability

How can you incentivize physicians to work more efficiently?

High-volume physicians who show savings can provide context for the results of others – what is driving savings?

Physicians that show losses may unearth useful patterns.



## Poll 3

### **Which area is your biggest barrier to success under CJR-X?**

- Data availability and analytics
- Quality performance improvement
- Post-acute care performance improvement
- Cross-organizational collaboration

# Translate your data to future savings

Three areas where early visibility converts directly into dollars – an example for a small hospital system

POTENTIAL FINANCIAL EXPOSURE (BASED ON STOP-LOSS)

**\$8,000,000**

01

## Financial Impact

If CJR-X occurred in 2025, your CJR-X mandated hospitals would be held financially accountable for **more than 1,600 episodes**, with total episode spending **over \$40 million**.

This high episode volume puts your potential financial exposure upwards of **\$8 million** for 2025 alone (based on stop-loss).

02

## Post-Acute Savings

There is substantial variation in post-acute utilization patterns across your CJR-X mandated hospitals, highlighting the need for detailed, facility-level insights.

For example, three of your hospitals could save **over \$200K each** if SNF utilization moved to the regional average and five hospitals could save **over \$100K each** if they reduced their readmissions to the regional average.

03

## Physician Variation


There can be substantial variation in performance between operating physicians, highlighting the need for detailed operating physician (OP) insights that support meaningful discussions around care pattern changes.

For example, two high-volume physicians have a similar patient mix, **but one is discharging patients to SNFs at nearly double benchmark rates**.

# Planning

What are the key dates and what to prepare for next

# How to Establish an Action Plan



# Framework for Evaluating Model Readiness



## Financial

- Given the benchmarking methodology and historical performance, do you have a reasonable chance to succeed in the model?



## Clinical

- Do you have clinical champions in key areas, willing to drive change?
- Does the model offer access to valuable tools, such as waivers?



## Operational

- Do you have the people, process, technology you need to be successful in the model?



## Relationships

- Do you have a broad enough network of providers to succeed in the model? If not, can you build one, or join one?

# Next Steps for Mandatory Participants



Analyze historical research data, as well as CMS-provided historical data, to inform preparation for participation based on volume, utilization, and opportunity




Work with internal stakeholders to better understand the implications of the program, align resources to manage the day-to-day, and focus on any service line modifications to achieve successful outcomes



Make a plan for ongoing data support to track your progress towards utilization and cost savings goals

# CJR-X is Coming, Whether You are Ready or Not.



Schedule a **CJR-X performance review** with our **Milliman MedInsight experts**. We will cover your clinical, financial, operational, and relationship-based opportunities and challenges.



Learn more how Milliman MedInsight tools can help facilitate your success. Book a call or demo. Contact us at [info@medinsight.com](mailto:info@medinsight.com)

**CJR-X is mandatory, but it is also a bridge to a value-based future.  
Prepare now to maximize your success.**

# Q&A

**Please drop your questions in the chat.**



[Visit our VBCExhibitHall.com Virtual Booth](https://VBCExhibitHall.com)



ENTER BOOTH

Milliman MedInsight

# Thank you

**Pamela Pelizzari**

[pamela.pelizzari@milliman.com](mailto:pamela.pelizzari@milliman.com)

**Alyssa Pennini**

[alyssa.pennini@milliman.com](mailto:alyssa.pennini@milliman.com)